BRD4 and leukemia: Genetic and shRNA-mediated silencing of BRD4 in MLL-AF9 driven leukemia models not only resulted in the removal of BRD4 from super-enhancers, including the MYC enhancer (93), but also in differentiation of leukemia cells and decrease of leukemogenic potential in vitro and in vivo.